Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR3 | P49682 | 5/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 5/20 | 0.40 |
| ▸ | NR1H3 | Q13133 | 5/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
| ▸ | SLC6A9 | P48067 | 4/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.38 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.37 |
| ▸ | LCAT | P04180 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.37 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14970181 | 0.97 | CXCR3 (0.41) | CXCR3NR1H2NR1H3GPR119CHRM4 | |
| SCHEMBL14969475 | 0.92 | CXCR3 (0.41) | CXCR3NR1H2NR1H3GPR119CHRM4 | |
| SCHEMBL14966416 | 0.87 | KCNH2 (0.45) | CXCR3NR1H2NR1H3GPR119CHRM4 | |
| SCHEMBL14969317 | 0.85 | KCNH2 (0.43) | CXCR3NR1H2NR1H3GPR119CHRM4 | |
| SCHEMBL14966354 | 0.84 | CXCR3 (0.42) | CXCR3NR1H2NR1H3GPR119CHRM4 | |
| SCHEMBL14969497 | 0.84 | SLC6A9 (0.43) | CXCR3NR1H2NR1H3GPR119CHRM4 | |
| SCHEMBL14966702 | 0.83 | SLC6A9 (0.44) | CXCR3NR1H2NR1H3GPR119CHRM4 | |
| SCHEMBL14978760 | 0.82 | CXCR3 (0.37) | CXCR3GPR119CHRM4SCN10ALCAT | |
| SCHEMBL14969159 | 0.82 | SLC6A9 (0.42) | CXCR3GPR119CHRM4SLC6A9KCNH2 | |
| SCHEMBL14969473 | 0.80 | NR1H2 (0.43) | CXCR3NR1H2NR1H3GPR119SLC6A9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140309226-A1 | PIPERIDINYL-SUBSTITUTED CYCLIC UREAS AS GPR119 MODULATORS | ARRAY BIOPHARMA, INC. | 2014-10-16 | — | — | US | disclosed |
| US-20140309226-A1 | PIPERIDINYL-SUBSTITUTED CYCLIC UREAS AS GPR119 MODULATORS | ARRAY BIOPHARMA, INC. | 2014-10-16 | — | — | US | disclosed |
| US-20140309226-A1 | PIPERIDINYL-SUBSTITUTED CYCLIC UREAS AS GPR119 MODULATORS | ARRAY BIOPHARMA, INC. | 2014-10-16 | — | — | US | disclosed |
| WO-2013074641-A1 | PIPERIDINYL- SUBSTITUTED CYCLIC UREAS AS GPR119 MODULATORS | ARRAY BIOPHARMA INC. (US) | 2013-05-23 | — | — | WO | disclosed |
| WO-2013074641-A1 | PIPERIDINYL- SUBSTITUTED CYCLIC UREAS AS GPR119 MODULATORS | ARRAY BIOPHARMA INC. (US) | 2013-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140309226-A1 | PIPERIDINYL-SUBSTITUTED CYCLIC UREAS AS GPR119 MODULATORS | GPR119, UTS2R, GPR139 | CXCR3 334/4885NR1H2 42/4885NR1H3 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.